Clinical evaluation of Bio-Oss®: A Bovine-Derived Xenograft for the treatment of periodontal osseous defects in humans

The purpose of this study was to compare the bovine derived xenograft (BDX) Bio-Oss® to demineralized freeze dried bone allograft (DFDBA) in human intrabony defects. 17 healthy patients with no systemic disease with moderate-severe periodontitis (7 males, 10 females; aged 34-67), were treated. Surgically, defects were included only if the intraosseous defect depth was >3.0 mm. Final selection included 30 defects. The sites were randomly assigned treatment with DFDBA or BDX. Soft tissue and osseous defect measurements were taken the day of surgery and 6 months post-operatively at re-entry. Average baseline PD, CAL, and surgical defect depth for the DFDBA group were not statistically different from the BDX group. No adverse healing response occurred. The results showed a statistically significant improvement in PD and AL for both materials at 6 months in 26 defects (4 defects did not respond to therapy). Soft tissue measurements for the DFDBA group included PD reduction of 2.0±1.3 mm, and AL gain of 2.6±1.6 mm, while the BDX group showed a PD reduction of 3.0±1.7 mm, and AL gain of 3.6±1.8 mm. Osseous measurements showed bone fill of 2.4 mm (46.8%) for the DFDBA group and 3.0 mm (55.8%) for the BDX group. Defect resolution was 59.4% for the DFDBA group and 77.6% for the BDX group. Statistical analysis revealed there was no statistical difference between the 2 materials in all measurements.